iSpecimen (NASDAQ:ISPC) Issues Earnings Results

iSpecimen (NASDAQ:ISPC) released its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, FiscalAI reports. iSpecimen had a negative return on equity of 531.78% and a negative net margin of 343.86%.The company had revenue of $0.05 million during the quarter.

iSpecimen Stock Down 3.2%

Shares of ISPC stock traded down $0.01 during trading hours on Wednesday, reaching $0.15. 1,494,035 shares of the company’s stock were exchanged, compared to its average volume of 7,621,088. iSpecimen has a fifty-two week low of $0.14 and a fifty-two week high of $3.18. The stock has a market capitalization of $1.49 million, a P/E ratio of -0.02 and a beta of 1.87. The business has a fifty day moving average price of $0.27 and a 200-day moving average price of $0.54.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC purchased a new stake in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen at the end of the most recent reporting period. Institutional investors own 13.62% of the company’s stock.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.